Crestor vs Repatha in Special Populations: A Head-to-Head Clinical Comparison

How Rosuvastatin and Evolocumab Differ at the Molecular Level

Rosuvastatin inhibits HMG-CoA reductase, the enzyme that controls the rate-limiting step in hepatic cholesterol synthesis. Blocking that enzyme forces liver cells to upregulate LDL receptors, pulling more LDL-C out of circulation. Evolocumab takes a complementary route: it binds PCSK9, a protease that would otherwise tag LDL receptors for degradation, keeping those receptors active and available far longer than they would be otherwise.

Why the Mechanism Difference Matters Clinically

Because the two drugs act at different points in LDL metabolism, combining them produces additive, not redundant, LDL lowering. That is the pharmacological rationale behind add-on PCSK9 inhibitor therapy in patients who are already on maximum-tolerated statin doses.

The ceiling LDL-C reduction for rosuvastatin monotherapy plateaus near 55% at the 40 mg dose; doubling from 20 mg to 40 mg adds only about 6% additional reduction (the "rule of 6s"). Evolocumab, added on top of that plateau, can cut the remaining LDL-C by roughly another 59%, producing combined reductions of 70% or more from statin-only baseline. FOURIER trial data confirms this.

Receptor Saturation and Dosing Flexibility

Rosuvastatin reaches peak plasma concentration in 3 to 5 hours, has a half-life of about 19 hours, and is dosed once daily. Evolocumab is available as 140 mg every two weeks or 420 mg once monthly, with both regimens producing equivalent LDL-C reductions in the FOURIER protocol. Patients who prefer fewer injections often opt for the monthly 420 mg auto-injector pen.

The JUPITER and FOURIER Trials: What the Numbers Actually Show

These two key studies are the backbone of any Crestor vs Repatha discussion, but they tested different populations and different outcomes, so comparing them directly requires careful interpretation.

JUPITER (Rosuvastatin, 2008)

JUPITER enrolled 17,802 patients with LDL-C <130 mg/dL but elevated high-sensitivity CRP (>2 mg/L), meaning traditional statin criteria would have excluded most of them. Rosuvastatin 20 mg daily reduced the primary endpoint (combined MI, stroke, arterial revascularization, hospitalization for unstable angina, or CV death) by 44% vs. Placebo (HR 0.56; 95% CI 0.46 to 0.69; P<0.00001) over a median follow-up of 1.9 years. JUPITER, NEJM 2008.

The trial was stopped early by the data safety monitoring board because the magnitude of benefit was unambiguous. LDL-C fell from a mean of 108 mg/dL to 55 mg/dL in the rosuvastatin arm, a reduction of approximately 49%.

FOURIER (Evolocumab, 2017)

FOURIER enrolled 27,564 patients who already had established atherosclerotic cardiovascular disease (ASCVD) and were on optimized statin therapy (roughly 69% on high-intensity statins at baseline). Evolocumab 140 mg Q2W or 420 mg monthly reduced the primary composite endpoint (CV death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) by 15% vs. Placebo (HR 0.85; 95% CI 0.79 to 0.92; P<0.001) over a median of 2.2 years. FOURIER, NEJM 2017.

Mean LDL-C at baseline was 92 mg/dL; evolocumab reduced it to 30 mg/dL. The absolute risk reduction was 1.5 percentage points, yielding a number needed to treat (NNT) of 67 over 2.2 years.

Reading Both Trials Together

JUPITER demonstrates that rosuvastatin alone produces dramatic risk reduction in primary-prevention patients with elevated inflammatory markers. FOURIER demonstrates that in secondary-prevention patients already on a statin, pushing LDL-C from ~90 mg/dL to ~30 mg/dL with evolocumab produces additional, measurable event reduction. The two drugs are not competing for the same slot; they typically occupy sequential positions on the same treatment ladder.

Special Populations: Who Gets Which Drug and Why

This is where the clinical decision-making gets detailed. Guidelines and trial subgroup data point to clear preferences for each agent depending on patient characteristics.

Patients with Chronic Kidney Disease (CKD)

Rosuvastatin is renally excreted. The FDA label specifies that CKD patients with eGFR <30 mL/min/1.73 m² should start at 5 mg daily and not exceed 10 mg daily. That dose cap limits achievable LDL-C reduction to roughly 35 to 40%, leaving many high-risk CKD patients above goal.

Evolocumab does not depend on renal elimination. In the FOURIER CKD subgroup (approximately 22% of the trial population had eGFR <60 mL/min/1.73 m²), no dose adjustment was required and the relative risk reduction was consistent with the overall trial result. For CKD stage 3b, 5 patients who need more than 35% LDL-C reduction, evolocumab may be the more practical agent. ACC/AHA Cholesterol Guideline 2018.

Patients with Type 2 Diabetes

Statins, including rosuvastatin, carry a well-documented signal for new-onset type 2 diabetes. JUPITER itself showed a 27% increase in physician-reported diabetes diagnoses in the rosuvastatin arm vs. Placebo (HR 1.27; 95% CI 1.05 to 1.53). This does not reverse the net CV benefit for patients with multiple risk factors, but it deserves disclosure during shared decision-making.

Evolocumab shows no diabetogenic signal. The FOURIER diabetic subgroup (approximately 40% of participants) showed consistent cardiovascular benefit without glucose metabolism changes. For patients with pre-diabetes, metabolic syndrome, or tight glycemic control requirements, choosing or preferring evolocumab over a high-dose statin may be reasonable in the context of individualized risk-benefit analysis.

Elderly Patients (Age 75 and Older)

Older patients are underrepresented in most statin trials. The FOURIER elderly subgroup (age >65, N=approximately 9,600) showed a numerically larger absolute risk reduction than the younger cohort, consistent with their higher baseline cardiovascular risk. Statin myopathy and rhabdomyolysis risk also increase with age, polypharmacy, and reduced muscle mass, all common in this group.

Evolocumab's adverse event profile in FOURIER showed no signal for muscle-related injury beyond placebo rates. For an 80-year-old on multiple medications with documented statin-associated muscle symptoms (SAMS), evolocumab offers a path to aggressive LDL-C control without the myopathy concern.

Statin-Intolerant Patients

Statin intolerance is estimated to affect 5 to 10% of statin users in real-world registries, with muscle symptoms being the most common complaint. The GAUSS-3 trial (N=511) tested evolocumab specifically in patients with confirmed statin intolerance (defined as two or more statins causing muscle symptoms) and demonstrated a 52.8% LDL-C reduction vs. A 1.0% reduction with ezetimibe (P<0.001). GAUSS-3.

The ACC/AHA 2018 guideline specifically endorses PCSK9 inhibitors for statin-intolerant very-high-risk patients: "In patients with clinical ASCVD who are truly statin intolerant, a PCSK9 inhibitor is reasonable to reduce the risk of ASCVD events." This makes evolocumab a first-choice option rather than a last resort in this group.

Patients with Familial Hypercholesterolemia (FH)

Heterozygous FH patients typically require 50 to 60% LDL-C reduction from an already elevated baseline to approach their LDL-C goal of <70 mg/dL (or <55 mg/dL in very-high-risk individuals). Rosuvastatin at 20 to 40 mg rarely achieves this alone when starting LDL-C values exceed 200 mg/dL.

FOURIER enrolled approximately 1,400 patients with FH at baseline. Evolocumab added to maximum-tolerated statin therapy brought the majority of HeFH patients below 70 mg/dL. For homozygous FH, evolocumab's efficacy depends on residual LDL-receptor activity and is substantially attenuated in patients with no functional receptors.

Switching from Crestor to Repatha: When and How

Switching is not the right frame for most patients. The clinical question is almost always whether to add evolocumab on top of rosuvastatin, not replace it. Three scenarios genuinely warrant a substitution rather than an addition.

Scenario 1: Documented Statin Intolerance

A patient with confirmed SAMS who cannot tolerate any statin (verified by statin rechallenge trial with two or more agents) should discontinue rosuvastatin and begin evolocumab. Ezetimibe 10 mg daily is typically added concurrently because the combination of ezetimibe plus evolocumab produces LDL-C reductions approaching 65 to 70% from baseline. Bempedoic acid (Nexletol) is an alternative non-statin addition in this group.

Scenario 2: CKD Stage 4 to 5 with LDL-C Above Goal

A patient on rosuvastatin 10 mg (the maximum allowed dose in severe CKD per FDA labeling) who remains well above the <70 mg/dL secondary-prevention target should be considered for evolocumab add-on or substitution under nephrology and cardiology co-management. The drug interaction profile with immunosuppressants common in dialysis or transplant patients should be reviewed separately.

Scenario 3: New Diabetes Diagnosis in a Pre-Diabetic Patient

The absolute CV benefit of statin therapy in patients without established ASCVD but with a new type 2 diabetes diagnosis is real, and the ACC/AHA guideline still recommends statin therapy for most diabetic adults aged 40 to 75. However, a patient on rosuvastatin for primary prevention who develops diabetes may be a candidate for switching to evolocumab if their LDL-C is borderline and their 10-year ASCVD risk is moderate rather than high. This requires individualized shared decision-making and should not be applied as a blanket policy.

Transition Protocol in Practice

The HealthRX clinical team uses a four-step transition checklist for patients moving from statin to evolocumab:

1. Confirm statin intolerance with a structured rechallenge log (at least two statin trials at lowest available dose over 4 to 6 weeks each).
2. Add ezetimibe 10 mg daily and check LDL-C at 6 weeks.
3. If LDL-C remains above goal (typically <70 mg/dL for secondary prevention, <55 mg/dL for very high risk), submit a prior authorization for evolocumab with documentation of statin trials and current LDL-C value.
4. Initiate evolocumab 140 mg Q2W; recheck fasting lipid panel at 8 to 12 weeks; titrate to 420 mg monthly if adherence or injection burden is a concern.

Side Effects, Tolerability, and Safety Signals

Rosuvastatin Safety Profile

Rosuvastatin is well-tolerated at doses up to 40 mg daily for most patients. Known adverse effects include:

• Myalgia (muscle pain without elevated CK): 1 to 5% in clinical trials, higher in real-world registries
• Elevated liver transaminases (>3x ULN): <1% in JUPITER
• New-onset type 2 diabetes: HR 1.27 in JUPITER as noted above
• Rhabdomyolysis: rare but serious; risk increases with cyclosporine, gemfibrozil, and lopinavir co-administration
• Proteinuria at 40 mg dose (dose-dependent; not seen at 5 to 10 mg)

The FDA label for rosuvastatin includes a contraindication for co-administration with cyclosporine and a dose limitation to 10 mg when given with certain HIV antiretrovirals. Asian patients may achieve higher plasma concentrations per dose and often do well on 5 to 10 mg rather than 20 to 40 mg.

Evolocumab Safety Profile

FOURIER followed 27,564 patients for a median of 2.2 years with reassuring safety data. The most common adverse events were injection-site reactions (2.1% evolocumab vs. 1.6% placebo). Neurocognitive events were initially a theoretical concern with very low LDL-C values; the EBBINGHAUS sub-study (N=1,204, nested within FOURIER) showed no difference in cognitive performance between evolocumab (median LDL-C 31 mg/dL) and placebo over 19 months. EBBINGHAUS.

No hepatotoxicity signal, no diabetogenic effect, and no meaningful muscle-related adverse events above placebo rates emerged in FOURIER. The long-term OSLER extension studies showed durable LDL-C reduction and no new safety signals at four-year follow-up.

Cost, Access, and Insurance Considerations

Rosuvastatin generic is widely available at $10, $30/month at retail pharmacies and often free through certain pharmacy discount programs. Branded Crestor carries a list price around $250/month but is rarely prescribed given generic availability.

Evolocumab's list price is approximately $5,800/year ($483/month) in the US as of 2024. Amgen's patient assistance program (REPATHA PAYSM) caps out-of-pocket costs at $5/month for commercially insured patients who qualify. Medicare Part D coverage varies by plan; prior authorization is required by virtually all commercial and government payers.

The Institute for Clinical and Economic Review (ICER) evaluated PCSK9 inhibitors and concluded in its 2020 update that evolocumab is cost-effective at a threshold of $150,000/QALY when LDL-C remains above 70 mg/dL on maximum-tolerated statin plus ezetimibe. Patients who clear that threshold are generally approvable under most payer criteria.

Guideline Positioning: Where Each Drug Sits on the Treatment Ladder

The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol places lipid-lowering therapy on an explicit stepwise ladder for secondary-prevention patients:

1. High-intensity statin (rosuvastatin 20 to 40 mg or atorvastatin 40 to 80 mg)
2. Add ezetimibe 10 mg if LDL-C remains >70 mg/dL
3. Add a PCSK9 inhibitor (evolocumab or alirocumab) if LDL-C remains >70 mg/dL after step 2

The guideline states: "For patients with very high-risk ASCVD, it is reasonable to add ezetimibe and, if necessary, a PCSK9 inhibitor to maximally tolerated statin therapy."

Evolocumab is also endorsed in the 2021 ESC/EAS guidelines for patients who cannot reach their LDL-C goal on maximum-tolerated statin plus ezetimibe, with a Class I, Level A recommendation in very-high-risk patients (10-year CV mortality risk >10%). ESC/EAS 2021 Dyslipidaemia Guidelines.

Head-to-Head Summary Table

| Feature | Rosuvastatin (Crestor) | Evolocumab (Repatha) | |---|---|---| | Drug class | Statin | PCSK9 inhibitor | | LDL-C reduction (mono) | 45 to 55% | 58 to 60% | | Route | Oral, once daily | Subcutaneous Q2W or monthly | | CKD dose adjustment | Yes (cap 10 mg if eGFR <30) | No adjustment needed | | Diabetogenic signal | Yes (HR 1.27, JUPITER) | No signal (FOURIER) | | Muscle symptom risk | Yes (1 to 10% SAMS) | No excess over placebo | | Key trial | JUPITER (N=17,802) | FOURIER (N=27,564) | | Guideline tier | First-line | Third-line (after statin + ezetimibe) | | Monthly cost (US) | $10, $30 generic | $450, $550 (before assistance) | | FH efficacy | Partial (rarely adequate alone) | High (reaches goal in most HeFH) |